The Ministry of Health of the Russian Federation has granted the N. N. Blokhin National Medical Research Center of Oncology (NMRC) permission to use the mRNA vaccine “Neovac RONTS.”
“The Center has received authorization for the medical use of an antitumor mRNA vaccine in patients with skin melanoma in an adjuvant setting — that is, in combination therapy within the framework of the scientific protocol established at the NMRC,” said Ivan Stilidi, Director of the NMRC.
The Ministry of Health clarified that the product will be “used following surgical treatment in patients aged 18 years and older with stage IIB–IV skin melanoma (after resection of all metastatic lesions) in combination with a PD-1 inhibitor.”
The personalized neoantigen-specific mRNA vaccine was developed jointly with the Gamaleya National Research Center for Epidemiology and Microbiology and the NMRC of Radiology. The vaccine will be prepared for individual patients using compounds synthesized based on the results of their genetic analyses.
Earlier, Minister of Health Mikhail Murashko described the mRNA platform-based vaccine as “a new generation of antitumor drugs, the efficacy and safety of which have yet to be evaluated.” Experts also recognize anticancer vaccines as one of the major achievements of Russian medicine in 2025. Full details are available in the GxP News article.